60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) shares popped Thursday. The Washington, D.C.-based company a pharmaceutical concern focused on developing new medicines for vector-borne disease, today announced a partnership with Runway Health to expand pre-departure access to ARAKODA® (tafenoquine) for prevention of malaria among international travelers through the Runway Health travel medicine platform.
ARAKODA is the only broad spectrum, once-weekly prescription malaria prevention on the U.S. market.
Runway Health is a direct-to-patient telehealth platform that enables adults to access physician-led online consultations before traveling to regions of the world where certain illnesses, including malaria, may be prevalent. If prescribed, seamless home delivery of medication arrives before departure.
Malaria, which is caused by the bite of the Anopheles mosquito, is one of the most serious, life-threatening infectious diseases in the world. It is a constant threat to those living in malaria-endemic regions and to international travelers to those areas. If left untreated, it can progress to severe malaria, which is often fatal.
The partnership with Runway Health commences April 2, 2026. It adds a new platform to the 60 Degrees Pharma ARAKODA marketing strategy, where eligible users can match their travel itinerary with a personalized medical treatment plan designed by a U.S. licensed healthcare provider.
SXTP shares $5.18, or 258.9%, to $7.18.
